Financial giants have made a conspicuous bearish move on Moderna. Our analysis of options history for Moderna MRNA revealed 8 unusual trades.
Delving into the details, we found 37% of traders were bullish, while 62% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $104,790, and 6 were calls, valued at $358,291.
Predicted Price Range
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $40.0 to $120.0 for Moderna over the last 3 months.
Volume & Open Interest Trends
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Moderna's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Moderna's whale trades within a strike price range from $40.0 to $120.0 in the last 30 days.
Moderna Option Volume And Open Interest Over Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| MRNA | CALL | TRADE | BEARISH | 01/17/25 | $95.00 | $106.4K | 290 | 0 |
| MRNA | PUT | SWEEP | NEUTRAL | 01/17/25 | $100.00 | $71.6K | 2.3K | 37 |
| MRNA | CALL | TRADE | BULLISH | 01/16/26 | $40.00 | $67.1K | 8 | 11 |
| MRNA | CALL | SWEEP | NEUTRAL | 01/17/25 | $100.00 | $63.6K | 1.3K | 39 |
| MRNA | CALL | SWEEP | BEARISH | 01/16/26 | $60.00 | $51.5K | 276 | 11 |
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
In light of the recent options history for Moderna, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Where Is Moderna Standing Right Now?
- With a trading volume of 1,397,103, the price of MRNA is down by -0.42%, reaching $94.66.
- Current RSI values indicate that the stock is is currently neutral between overbought and oversold.
- Next earnings report is scheduled for 59 days from now.
Expert Opinions on Moderna
In the last month, 3 experts released ratings on this stock with an average target price of $100.66666666666667.
- An analyst from Canaccord Genuity has decided to maintain their Hold rating on Moderna, which currently sits at a price target of $91.
- An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $125.
- An analyst from HSBC has revised its rating downward to Reduce, adjusting the price target to $86.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
